NCE-1 Intelligence & Market Opportunity

Leqvio

Inclisiran

Antihyperlipidemic

Subcutaneous Solution

Approval Date

22-Dec-21

NCE-1 Date

22-Dec-25

NCE Date

22-Dec-26

Commercial snapshot

Market performance & projections

Revenue ($M)

1372

CAGR (%)

0.2812

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2030

2027

2632

2028

3248

2029

3697

2030

4100

2031

4461

2032

4837

Molecule profile

Details & specifications

Molecule

Inclisiran

Innovator

NOVARTIS PHARMACEUTICALS CORPORATION

Dosage Form

Subcutaneous Solution

Strength

EQ 284 mg base/1.5 mL (EQ 189 mg base/mL)

Therapeutic Category

Antihyperlipidemic

Usage

To treat heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease as an add-on therapy

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.